News

French pharmaceutical group Sanofi-Aventis has announced an increase of capital investment in the amount of $90m to extend its current manufacturing facility located at the Beijing Economic and

Tolarex, a Hadasit Bio Holdings portfolio company, has received approval from the Ministry of Health of Israel to begin a Phase I/IIa clinical trial of its treatment for

SpePharm, a Dutch specialty pharmaceutical company, has introduced two new products, MuGard and Xerotin, aimed at relieving some of the most debilitating side effects experienced by cancer patients,

The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client

Since its introduction in December 1993, Cravit has gained approval for treating 43 indications and 32 bacteria, the company said. Daiichi Sankyo drew on PK-PD theory to develop

Coldizin is scheduled for launch in the third quarter, in time for the ‘cough and cold season’, and Immulina is planned for launch in the fourth quarter. thin400

Alnylam Pharmaceuticals, an RNAi therapeutics company, has reported that the European Patent Office has issued a notification of intent to grant for a patent in the Tuschl I

With the CE-Marking, Biomerica said that its new one-step test can now be marketed directly to consumers through pharmacies in the EU. Biomerica’s home test, which will be

Biolex Therapeutics, a biopharmaceutical company, has started patient dosing in the Select-2 Phase IIb trial of its lead product candidate Locteron for the treatment of chronic hepatitis C.